Title: Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations

Authors: Jingjing Yu, Yan Wang, and Isabelle Ragueneau-Majlessi

UW Drug Interaction Solutions, Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA (J.Y., Y.W., I.R-M.)

Journal: Drug Metabolism and Disposition

Manuscript ID: DMD-MR-2021-000401

Supplemental Table 1. Clinical indications and chemical structures of small molecular drugs approved by the FDA in 2020

NDA Number	**Drug Name (CAS Registry Number)**	**Clinical Indications[a]**	**Structure[b]**
206966	abametapir (1762-34-1)	a pediculicide indicated for the topical treatment of head liceinfestation in patients 6 months of age and older	

209510	amisulpride (71675-85-9)	a dopamine-2 antagonist indicated in adults for: (1) prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class; (2) treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis	
213036	artesunate (88495-63-0)	an antimalarial indicated for the initial treatment of severe malaria in adult and pediatric patients	

212608	avapritinib (1703793-34-3)	a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor harboring a platelet-derived growth factor receptor alpha exon 18 mutation	
211616	bempedoic acid (738606-46-7)	an adenosine triphosphate-citrate lyase inhibitor indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C	

214094	berotralstat (1809010-50-1)	a kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older	
213591	capmatinib (1029712-80-8)	a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to mesenchymal-epithelial transition exon 14 skipping	

212576	cedazuridine and decitabine (1141397-80-9 and 2353-33-5)	cedazuridine, a cytidine deaminase inhibitor, co-packaged with decitabine, a nucleoside metabolic inhibitor, indicated for treatment of adult patients with myelodysplastic syndromes	 
213433	clascoterone (19608-29-8)	an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age or older	

213227	copper Cu-64 dotatate (1426155-87-4)	a radioactive diagnostic agent indicated for use with positron emission tomography for localization of somatostatin receptor positive neuroendocrine tumors in patients	
212123	flortaucipir F 18 (1522051-90-6)	a radioactive diagnostic agent containing the isotope fluorine 18. It is indicated for the evaluation of suspected Alzheimer's disease via positron emission tomography imaging of the brain	

212155	fluoroestradiol F-18 (94153-53-4)	a radioactive diagnostic agent indicated for use with positron emission tomography imaging for the detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer	
212950	fostemsavir (864953-29-7)	a human immunodeficiency virus type 1 (HIV-1) gp120-directed attachment inhibitor, in combination with other antiretroviral(s), indicated for the treatment of HIV-1 infection in heavily treatment-experienced patients with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations	

212642	gallium GA 68 PSMA-11 (1906894-20-9)	a peptide-based radioactive diagnostic agent indicated for positron emission tomography imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer meeting certain criteria	
211281	lactitol (585-86-4)	an osmotic laxative indicated for the treatment of chronic idiopathic constipation in adults	

213969	lonafarnib (193275-84-2)	a farnesyltransferase inhibitor indicated in patients 12 months and older for the treatment of Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies	
214103	lumasiran (1834610-13-7)	a hydroxyacid oxidase 1-directed small interfering ribonucleic acid indicated for the treatment of primary hyperoxaluria type 1 in pediatric and adults	

213702	lurbinectedin (497871-47-3)	an alkylating drug indicated for the treatment of adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy	
213464	nifurtimox (23256-30-6)	a nitrofuran antiprotozoal indicated in pediatric patients (birth to less than 18 years of age) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi	

210730	oliceridine (1401028-24-7)	an opioid agonist indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate	
212489	opicapone (923287-50-7)	a catechol-O-methyltransferase inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes	

212801	osilodrostat (928134-65-0)	a cortisol synthesis inhibitor indicated for Cushing's disease for whom pituitary surgery is not an option or has not been curative	
209899	ozanimod (1306760-87-1)	a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis	

213736	pemigatinib (1513857-77-6)	a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement	
213721	pralsetinib (2097132-94-8)	a kinase inhibitor indicated for the treatment of metastatic non-small cell lung cancer harboring the rearranged during transfection fusion-positive gene	

214621	relugolix (737789-87-6)	a gonadotropin-releasing hormone antagonist indicated for the treatment of patients with advanced prostate cancer	
214787	remdesivir (1809249-37-3)	a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatrics (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 requiring hospitalization	

212295	remimazolam (308242-62-8)	a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 min or less. It is recommended to individualize and titrate dosing to desired clinical effect	
212728	rimegepant (1289023-67-1)	a calcitonin gene-related peptide receptor antagonist indicated for the treatment of acute migraine in adults	

213973	ripretinib (1442472-39-0)	a kinase inhibitor indicated for the treatment of advanced gastrointestinal stromal tumor in patients who have received prior treatment with 3 or more kinase inhibitors, including imatinib	
213535	risdiplam (1825352-65-5)	a survival of motor neuron 2 splicing modifier indicated for the treatment of spinal muscular atrophy	

213246	selpercatinib (2152628-33-4)	a kinase inhibitor indicated for the treatment of non-small cell lung cancer and thyroid cancer with specific RET gene mutations	
213756	selumetinib (606143-52-6)	a kinase inhibitor indicated for the treatment of pediatric patients (2 years and older) with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas	

213793	setmelanotide (920014-72-8)	a melanocortin 4 receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance	
211723	tazemetostat (1403254-99-8)	a methyltransferase inhibitor indicated for the treatment of patients 16 years and older with metastatic or locally advance epithelioid sarcoma not eligible for complete resection	

213189	tirbanibulin (897016-82-9)	a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp	
213687	triheptanoin (620-67-7)	a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with long-chain fatty acid oxidation disorders	

213411	tucatinib (937263-43-9)	a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer	
213006	vibegron (1190389-15-1)	a beta-3 adrenergic agonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults	

212154	viltolarsen (2055732-84-6)	an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping	 CCTCCGGTTC TGAAGGTGTTC

[a] Clinical indications were obtained from each drug's Product Label available at Drugs@FDA, accessed in September 2021.

[b] Chemical structure was obtained from https://chem.nlm.nih.gov/chemidplus/ accessed August 2021, except gallium GA 68 PSMA-11, lumasiran, and viltolarsen whose structures were obtained from the Gallium GA 68 PSMA-11, OXLUMO, and VILTEPSO Product Label, respectively.